Tarceva

AZ speeds first-line lung cancer filing for Tagrisso to EMA

AZ describes Tagrisso as a third-generation EGFR inhibitor, with advantages over first-line agents - its own Iressa (gefitinib) product and Roche's Tarceva (erlotinib) - not only in efficacy but also ... In FLAURA, the median duration of response was

Prospects for Lilly’s Verzenio hit by botched lung cancer trial

The study compared Verzenio to Roche’s EGFR inhibitor Tarceva (erlotinib), which when it started in 2015 was the only agent indicated for second- and third-line therapy in advanced NSCLC,

AZ starts pursuit of lung cancer indication for Imfinzi

In that study, patients on Tagrisso had a PFS of 18.9 months, compared to just over 10 months for first-generation EGFR-targeting drugs, Roche's Tarceva (erlotinib) and

AZ buoyed by latest lung cancer data at ESMO

to just over 10 months for first-generation EGFR-targeting drugs, Roche's Tarceva (erlotinib) and AZ's own Iressa (gefitinib).

AZ gets rapid approval in China for Tagrisso

Moreover, nearly two thirds patients whose disease progresses after treatment with a first-line EGFR inhibitor - such as Iressa, Roche/Astellas' $2bn-a-year Tarceva (erlotinib) and Boehringer Ingelheim's Giotrif

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]